[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100503999":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":29,"locations":36,"responsibleParty":67,"collaborators":24,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":24,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":94,"whyStopped":24,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Hospices Civils de Lyon","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Crohn's Disease Group","EXPERIMENTAL","Patients followed for a Crohn's Disease in consultation or in day hospital aged between 6 and 18 years old.",[13,14],"Other: Blood samples","Other: Biopsies",{"label":16,"type":6,"description":17,"interventionNames":18},"Control Group","Patients followed for functional abdominal disorders",[13,14],[20,25],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"Blood samples","Blood sample of maximum 20ml (5 tubes of EDTA of 4ml or 5 tubes of EDTA of 2ml and a tube for the conservation of genomic DNA)",[16,9],null,{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Biopsies","5 biopsies (one for each segment of the intestine explored: ileum, right colon, transverse colon left colon and sigmoid) will be taken during the ileocolonoscopy",[16,9],[30],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"Rémi DUCLAUX-LORAS, MD, PhD","CONTACT","0472357050","+33","remi.duclaux-loras@chu-lyon.fr",[37],{"facility":38,"status":24,"city":39,"state":24,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Service Hépatologie, Gastroentérologie et Nutrition pédiatrique, Hôpital Femme Mère Enfant, HCL","Bron","69500","France","FR",{"type":44,"coordinates":45},"Point",[46,47],4.91303,45.73865,{"lat":47,"lon":46},[50,52,54,57,59,61,63,65],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":51},"Remi.duclaux-loras@chu-lyon.fr",{"name":31,"role":53,"phone":24,"phoneExt":24,"email":24},"PRINCIPAL_INVESTIGATOR",{"name":55,"role":56,"phone":24,"phoneExt":24,"email":24},"Nicolas CARON, MD","SUB_INVESTIGATOR",{"name":58,"role":56,"phone":24,"phoneExt":24,"email":24},"Sophie HEISSAT, MD",{"name":60,"role":56,"phone":24,"phoneExt":24,"email":24},"Barbara ROHMER, MD",{"name":62,"role":56,"phone":24,"phoneExt":24,"email":24},"Noémie LAVERDURE, MD",{"name":64,"role":56,"phone":24,"phoneExt":24,"email":24},"Mathias RUIZ, MD",{"name":66,"role":56,"phone":24,"phoneExt":24,"email":24},"Pierre POINSOT, MD",{"type":68,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100503999","autophagy-in-paediatric-crohns-disease-100503999",false,"NCT05842564","Autophagy in Paediatric Crohn's Disease","Autophagic Activity Characterization in Pediatric Crohn's Disease","P-IBDphagy","Inclusion Criteria:\n\nFor Crohn's Disease group :\n\n* Age between 6 and 17 inclusive\n* Patients with a weight \\> 25 kg at the time of inclusion\n* Patients with Crohn's disease requiring ileocolonoscopy (diagnosis or follow-up)\n* Mild to severe Crohn's disease consistent with PCDAI disease activity score\n* Patients on nutritional therapy (Modulen\u002FModulife), corticosteroids, salicylic derivatives, immunosuppressants, biotherapies (anti-TNF, vedolizumab and ustekinumab) or without treatment\n* Consent form signed by the patient or the holder(s) of parental authority.\n* Affiliation to a social security scheme or beneficiaries of a similar scheme.\n\nFor Control group:\n\n* Between 6 and 17 years old included\n* Presenting a weight \\> 25 kg at the time of inclusion\n* Without a diagnosis of Crohn's disease\n* Requiring evaluation by ileoendoscopy\n* Consent form signed by the patient or the holder(s) of parental authority.\n* Affiliation to a social security scheme or beneficiaries of a similar scheme.\n\nExclusion Criteria:\n\n* Refusal to participate in the protocol\n* Intercurrent infection\n* Ongoing antibiotic treatment\n* Patient involved in another interventional study protocol including an exclusion period still in progress at pre-inclusion\n* Pregnant, parturient or breastfeeding women (on questioning)\n* Persons deprived of their liberty by a judicial or administrative decision\n* Persons subject to psychiatric care\n* Persons admitted to a health or social establishment for purposes other than research","ALL","6 Years","17 Years",{"count":81,"type":82},70,"ESTIMATED","INTERVENTIONAL",[85],"NA","Crohn's disease is a multifactorial complex disease resulting in a between microbiota and immune system. Indeed, GWAS (Genome-Wide Association Studies) association study pinpointed polymorphisms as genes susceptibility on more than 200 loci. Among them genes coding for proteins involved in autophagy machinery (i.e: ATG16L1, IRGM et NDP52). Autophagy is a ubiquitous intracellular mechanism mandatory for protein and microorganism recycling.\n\nSo far, the role of autophagy in gut inflammation and intestinal homeostasis in Crohn's disease patients is partially understand. Then, investigators plan to evaluate, on native cells, the autophagic flux in pediatric patients suffering of a Crohn's disease compare to controls.",[88,89],"Crohn Disease","Pediatric Crohns Disease",[91,92,93],"Crohn's Disease","Autophagy","Polymorphism","NOT_YET_RECRUITING","2024-12-11",{"date":97,"type":98},"2024-12-12","ACTUAL",{"date":100,"type":82},"2025-01",{"date":102,"type":82},"2027-04",{"name":5,"class":6},1]